000			01939 a2200577 4500
005			20250515064826.0
264		0	_c20071128
008			200711s 0 0 eng d
022			_a1532-6535
024	7		_a10.1038/sj.clpt.6100195 _2doi
040			_aNLM _beng _cNLM
100	1		_aThanacoody, R H K
245	0	0	_aFactors affecting drug concentrations and QT interval during thioridazine therapy. _h[electronic resource]
260			_bClinical pharmacology and therapeutics _cNov 2007
300			_a555-65 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAge Factors
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAlleles
650	0	4	_aAntipsychotic Agents _xadministration & dosage
650	0	4	_aAryl Hydrocarbon Hydroxylases _xgenetics
650	0	4	_aCross-Sectional Studies
650	0	4	_aCytochrome P-450 CYP2C19
650	0	4	_aCytochrome P-450 CYP2D6 _xgenetics
650	0	4	_aDopamine Antagonists _xadverse effects
650	0	4	_aFemale
650	0	4	_aGenetic Variation
650	0	4	_aGenotype
650	0	4	_aHeart Conduction System _xdrug effects
650	0	4	_aHumans
650	0	4	_aLinear Models
650	0	4	_aLong QT Syndrome _xblood
650	0	4	_aMale
650	0	4	_aMesoridazine _xadverse effects
650	0	4	_aMiddle Aged
650	0	4	_aMixed Function Oxygenases _xgenetics
650	0	4	_aRisk Factors
650	0	4	_aSchizophrenia _xdrug therapy
650	0	4	_aSex Factors
650	0	4	_aSmoking _xadverse effects
650	0	4	_aThioridazine _xadministration & dosage
650	0	4	_aWhite People _xgenetics
700	1		_aDaly, A K
700	1		_aReilly, J G
700	1		_aFerrier, I N
700	1		_aThomas, S H L
773	0		_tClinical pharmacology and therapeutics _gvol. 82 _gno. 5 _gp. 555-65
856	4	0	_uhttps://doi.org/10.1038/sj.clpt.6100195 _zAvailable from publisher's website
999			_c17009707 _d17009707